Navigation Links
Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate

$600,000 grant supports company’s novel Kv1.3 inhibitor program

Seattle, WA (PRWEB) March 29, 2010 -- Kineta, Inc. announced today receipt of a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Awarded under the NIAID’s expanded Phase 1 program, the $600,000, two-year grant will help finance IND-enabling studies of ShK-186, Kineta’s first-in-class therapeutic for type 1 diabetes mellitus, multiple sclerosis and other autoimmune diseases. The award includes a subcontract to George Chandy, M.D., Ph.D. of the University of California at Irvine for mechanistic studies. Kineta intends to begin human clinical trials on the investigational drug in the second half of 2010.
“This SBIR award is great validation of the importance and novelty of Kineta’s autoimmune program.    The funding adds to Kineta’s financial horsepower as we conclude preclinical studies and move into man later this year,” said Charles L. Magness, Ph.D., President and Chief Executive Officer of Kineta, Inc.
"It is very gratifying to see the high level support for ShK-186, and to witness its steady momentum through the development pipeline," added Dr. Chandy.
ShK-186 is a potent and highly specific Kv1.3 potassium channel blocker. It is designed to suppress activation of effector memory T cells, which are important mediators of inflammation and tissue damage in MS, type 1 diabetes mellitus and other autoimmune diseases. The drug candidate has been shown to significantly reverse disease in animal models of MS and rheumatoid arthritis. Animal models also have demonstrated that efficacy is achieved without the generalized immunosuppression that occurs with competing therapies. The synthetically manufactured compound was originally isolated from the Caribbean sea anemone, Stichodactyla helianthus, and subsequently optimized by Dr. Chandy’s laboratory.
For more information on today’s announcement or to schedule interviews contact, Meg O’Conor, Director of Corporate Communications and Investor Relations, 206-251- 8638

Kineta, Inc. is a Seattle-based, privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system. Our world class scientists are pioneers in developing life-changing drugs that harness the power of the immune system to fight disease. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases. Our progressive business model focuses on targeting unmet medical needs and on rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website,

The project described is supported by Award Number 1 R43 AI85691-01 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases or the National Institutes of Health.

This document contains forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties which could significantly affect expected results in the future from those expressed in any such forward-looking statements made by, or on behalf of Kineta One, LLC (the “Company” or “Subsidiary”) or Kineta, Inc. (the “Parent”).


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. New York College of Osteopathic Medicine (NYCOM) at NYIT Awarded $1 Million Federal Grant
2. Bloomberg School of Public Health awarded $15 million for laboratory renovation and modernization
3. Centenes Arizona Behavioral Health Unit Awarded Expanded Contract
4. MEDNET and Hielix Awarded the State of North Dakota Contract for Statewide Health Information Exchange (HIE) Strategic and Operational Plans
5. Hard to Treat Diseases (HTDS) Awarded Two Antibiotics Certificates For Chile
6. $300,000 CIHR grant awarded to Medicago, the Research Institute of the MUHC and McGill University
7. $250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research
8. $250,000 grant awarded for groundbreaking ligament and tendon repair research
9. San Diego Unified School District Awarded Silent Hero Grant From got breakfast?(R) Foundation
10. Mimotopes Awarded Major Peptide Supply Contract by the Queensland Institute of Medical Research in the Search for an Effective Malaria Vaccine
11. Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites
Post Your Comments:
Related Image:
Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: